Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients

Lupus

Volumn 15, Issue 9, 2006, Pages 584-589

  Bosch, X ^a   Guilabert, A ^a   Pallares L ^b   Cervera, Richard ^a,c   Ramos Casals, M ^a   Bove A ^a   Ingelmo, M ^a   Font, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Hypocomplementaemia; Infection; SLE; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEPHRITIS; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; STEROIDS;

EID: 33750523227     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306071919     Document Type: Article

References (31)

1. Merrill M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematososus. J Chronic Dis 1955; 1: 12-32.
2. Swaak AJG, Nossent J, Bronsveld W et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 447-454.
3. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age of onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 37-48.
4. Gladman DD. Prognosis of systemic lupus erythematosus and the factors that affect it. Curr Opin Rheumatol 1991; 3: 789-796.
5. Lee P, Urowitz MB, Bookman AAM et al. A review of 110 cases with particular reference to lupus nephritis, CNS manifestations, infections, aseptic necrosis and prognosis. Q J Med 1977; 46: 1-32.
6. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus: II. Causes of death. Arthritis Rheum 1982; 25: 612-617.
7. Petri M, Genovese M. Incidence and risk factors for hospitalization in systemic lupus erythematosus. J Rheumatol 1992; 19: 1559-1565.
8. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow up of an inception cohort. Arthritis Rheum 1995; 38: 1492-1499.
9. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre. I. Causes of death. J Rheumatol 1995; 22: 1259-1264.
10. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY. Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999; 17: 539-545.
11. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000; 39: 399-406.
12. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine 1999; 78: 167-175.
13. Blanco FJ, Gomez-Reino JJ, de la Mata J et al. Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 1998; 7: 159-163.
14. Duffy KN, Duffy CM, Gladman DD. Infection and disease actitivity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991; 18: 1180-1184.
15. Petri M, Genovese. Incidence of and risk factors for hospitalization in systemic lupus erythematosus. A prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992; 19: 1559-1565.
16. Paton NI, Cheong IK, Kong NC, Segasothy M. Risk factors for infection in Malaysian patients with systemic lupus erythematosus. Q J Med 1996; 89: 531-538.
17. Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sanchez L, Jimenez-Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001; 10: 505-510.
18. Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974; 17: 1-10.
19. Lacks S, White P. Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 1990; 17: 941-945.
20. Kahl LE. Herpes Zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994; 21: 84-86.
21. Manzi S, Kuller LH, Kutzer J et al. Herpes Zoster in systemic lupus erythematosus. J Rheumatol 1995; 22: 1254-1258.
22. Chan AY, Hooi LS. Outcome of 85 lupus nephritis patients treated with intravenous cyclophosphamide: a single centre 10 year experience. Med J Malaysia 2000; 55: 14-20.
23. Gladman DD, Hussain F, Ibañez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11: 234-239.
24. Noel V, Lortholary O, Cassasus P et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 1141-1144.
25. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 19: 1475-1482.
26. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
27. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
28. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumathol 2003; 15: 528-534.
29. Hidalgo-Tenorio C, Jimenez-Alonso J, de Dios Luna J, Tallada M, Martinez-Brocal A, Sabio J. Urinary tract infections and lupus erythematosus. Ann Rheum Dis 2004; 63: 431-437.
30. Garred P, Madsen HO, Halberg P et al. Mannose-binding lectin polymorphims and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2145-2152.
31. Garred P, Voss A, Madsen HO, Junker P. Association of mannosebinding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2: 442-450.